Dysmenorrhea Treatment Market: Increasing prevalence of Dysmenorrhea and growing research and development activities to boost Market growth

Global Dysmenorrhea Treatment Market size was valued at USD 5945.9 Mn in 2022 and is expected to reach USD 10457.37 Mn by 2029, at a CAGR of 8.4 %.
Overview
Dysmenorrhea is the medical term for painful menstrual periods that are caused due to uterine contractions. Generally, the pain is in the pelvis or lower abdomen and symptoms such as diarrhoea, fatigue and mood swings typically last less than three days during menstrual periods. Pain relief medication such as paracetamol, and regular exercise, release natural chemicals which relieve pain are the treatment options for period pain. The report includes a detailed analysis of Dysmenorrhea Treatment industry potential, historical data, current trends and future trends and upcoming opportunities. The primary and secondary data collection methods to collect data for the qualitative and quantitative analysis of the Dysmenorrhea Treatment industry.



To know about the Research Methodology :- Request Free Sample Report
Dysmenorrhea Treatment Market Dynamics
Drivers

Increasing prevalence of Dysmenorrhea to boosts the market growth

Genetic factors, stress, depression, and anxiety are the main factors associated with Dysmenorrhea and menstrual disorders. The women’s age parity and use of oral contraceptives have been inversely related to Dysmenorrhea. The factors such as cigarette smoking, pelvic infections, eating fast food, a low body mass index (BMI), diet, a history of sexual assault, and obesity are also causing the problem of Dysmenorrhea. The unfavourable effects of Dysmenorrhea have been caused by an individual’s psychological status, and health-related quality of life (HRQoL) might be disrupted among adolescent women. Around 40 percent, of the menstrual period pain is assisted by premenstrual symptoms including bloating, tender breasts, lack of concentration mood swings and tiredness. All these factors help to increase the prevalence of Dysmenorrhea and influence market growth.

Increasing research and development activities about Dysmenorrhea to fuel the market

The development of the Dysmenorrhea Symptom Interference scale has been used to measure the scales of the Dysmenorrhea Symptom interference with physical, mental and social activities. These measures are divided into generic pain measures and tools designed to measure premenstrual symptoms and varying degrees of exhaustiveness of symptoms measured, relevance to PD, multidimensionality and psychometric soundness. On the other hand, development of the innovative drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and spasmolytic have been tested, exhibiting the large potential for research for the development of effective combinations and introducing the new combination of drugs for Dysmenorrhea. As a result, research and development activities boost the Dysmenorrhea Treatment Market growth.

Dysmenorrhea Treatment Market Opportunity

The newly launched products for treating the pain associated with primary and secondary Dysmenorrhea such as Nonsteroidal anti-inflammatory drugs (NSAIDs), oral contraceptive pills (OCPs) and progestin-only pills (POPs). These products have been helpful in reducing menstrual pains and managing moderate to severe pain regards with endometriosis. In addition, the increase in awareness about reproductive health resulted to rising the new start-ups that offer period care such as menstrual cups and menstrual sterilizers which are affordable and electrical.

For example: The start-up was founded in 2020, by Vaishnavi Raju. The Hyderabad-based focuses on women’s healthcare by initiating friendly conservation around sexual intimacy, menopause, fertility pregnancy and menstruation.

Dysmenorrhea Treatment Market Restraints

Lack of public awareness, high cost of care and insufficient reimbursement policies restrain the Dysmenorrhea Treatment Market expansion. The side effects and issues of the Dysmenorrhea Treatment such as high morbidity of menstrual cramps due to inadequacy of the testaments also negatively affect the market potential. The traditional family values and long-term treatment of Dysmenorrhea Treatment hamper the growth of the market.
Dysmenorrhea Treatment Market Regional Insights
North America dominated the Dysmenorrhea Treatment Market and is expected to continue its dominance during the forecast period. The increasing prevalence and incidence of Dysmenorrhea, the presence of the major product manufacturers, growing awareness regarding the disease among women and the well-established healthcare sector are the influencing factors for the regional market growth.

The United States is expected to have significant growth for Dysmenorrhea Treatment and drive the regional market growth. The presence of the key market players, approval of new drugs by the FDA, increasing research and development activities and increasing healthcare expenditure are the influencing factors for the growth of the market. The increasing launching of new products for treating pain which is associated with primary as well as secondary dysmenorrhea and the consumption of the pharmaceuticals are also growth contributors to the United States market.

Europe is expected to grow at a significant CAGR for the Dysmenorrhea Treatment Market during the forecast period. The increasing prevalence of menstrual health issues and Dysmenorrhea, the growing number of research and development activities, increasing investment in the healthcare sector, and increasing demand for effective treatments for Dysmenorrhea, expansion of the healthcare

infrastructure, growing initiatives by the government and pharmaceutical companies are the boosting factors for the regional market growth.
Dysmenorrhea Treatment Market Segmentation
Based on Type

Based on Type, the market is categorized into Primary Dysmenorrhea and Secondary Dysmenorrhea. Primary Dysmenorrhea dominated the market and is expected to dominate the market over the forecast period. Primary Dysmenorrhea is more effective rather than Secondary Dysmenorrhea. Due to primary Dysmenorrhea, Aleve's single maximum non-prescription dose offers more pain relief lasting 12 to 72 hours than acetaminophen for menstrual cramps. Also, In Primary Dysmenorrhea, painful menstrual cramps occur one or two days before menstrual bleeding. It is happening in the lower abdomen, back, or thigh and is very painful for menstrual cramps. As a result, Primary Dysmenorrhea boosts market growth.

Based on the Treatment Type

On the basis of the Treatment Type Non-steroidal Anti-inflammatory Drugs (NSAIDs), Hormonal Therapy, Pain Reliever, Surgery and Others. In 2022, Nonsteroidal anti-inflammatory drugs (NSAIDs) held the largest market share and are expected to grow at a significant CAGR for the market. Nonsteroidal anti-inflammatory drugs (NSAIDs), a well-established therapy and first-line treatment for Dysmenorrhea and relieve primary Dysmenorrhea, suppress the endometrial production of endometrial prostaglandins, encourage cramps and restore better and normal uterine activity. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the action of cyclooxygenase (COX), which enzymes responsible for the formation of prostaglandins. All the factors contributing to the growth of the Non-steroidal Anti-inflammatory Drugs (NSAIDs) segment.

Based on End-Users

Based on the End-users, the market is divided into Hospitals, Homecare, Specialty Centres and Others. Hospitals are expected to witness a significant market share over the forecast period. The increasing prevalence of Dysmenorrhea resulted in to increase in the treatments for it which are largely available in hospitals. The treatments such as paracetamol, aspirin, and NSAIDs reduce the activity of cyclooxygenase pathways, therefore inhibiting the production of prostaglandin. Oral contraceptives word by constraining ovulation. Basically, all the treatments available in the hospital and thus hospital is the more dominating segment than the other.
Dysmenorrhea Treatment Market Competitive Landscape
Some of the Dysmenorrhea Treatment Market key players are Novartis AG,Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, and Focus Consumer Healthcare. These key players have adopted strategies including pricing, investments, expansion of the product portfolio, mergers and acquisitions, collaboration, agreements and geographical expansion for the enhancement of the Dysmenorrhea Treatment industry. The companies have been developing and launches of new drugs and creating awareness about the prevalence dysmenorrhea of related to the treatment of Dysmenorrhea.
For example, Novartis AG

The company recommended initial daily dose is 100 to 150 mg. In milder cases, 75 to 100 mg daily is usually sufficient. Generally, the total daily dose should be divided into 2 or 3 separate doses, as applicable. In primary dysmenorrhea, the daily dose should be individually adjusted and is generally 50 to 150 mg. An initial dose of 50mg is usually sufficient. Treatment should be started on the appearance of the first symptoms and, depending on the symptomatology continued for a few days. Clinical studies have also revealed that in primary dysmenorrhea the active substance is capable of relieving the pain and reducing the extent of bleeding.
Dysmenorrhea Treatment Market Scope: Inquire before buying



Dysmenorrhea Treatment Market


Report Coverage
Details


Base Year:
2022
Forecast Period:
2023-2029


Historical Data:
2017 to 2022
Market Size in 2022:
USD 5945.9 Mn


Forecast Period 2023 to 2029 CAGR:
8.4 %
Market Size in 2029:
USD 10457.37 Mn


 Segments Covered:
by Type
Primary Dysmenorrhea
Secondary Dysmenorrhea


by Treatment Type
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Hormonal Therapy
Pain Reliever
Surgery
Others


by End-Users
Hospitals
Homecare
Specialty Centres
Others


by Diagnosis
CT Scan
Laparoscopy
Magnetic Resonance Imaging
Ultrasound.


by Mode of Prescription
Counter
Prescription


by Route of Administration
Implants
Oral
Parenteral


by Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy



Dysmenorrhea Treatment Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and the Rest of APAC)
South America (Brazil, Argentina Rest of South America)
Middle East & Africa (South Africa, GCC, Egypt, Nigeria and the Rest of ME&A)
Dysmenorrhea Treatment Key Players
1. Novartis AG
2. Bayer AG
3. Abbott Laboratories
4. F. Hoffmann-La Roche Ltd
5. Sanofi, Pfizer Inc.
6. GlaxoSmithKline PLC
7. Focus Consumer Healthcare
8. Johnson & Johnson
9. Alvogen
10.Amgen Inc. (U.S.)
11.Boehringer Ingelheim International GmbH.
12.Ipsen Pharma
13.Spectrum Pharmaceuticals, Inc.
14.Takeda Pharmaceutical Company Limited.
15.BeyondSpring Inc.
16.Apotex Inc.
17.Taj Pharmaceuticals, Limited.
18.Sanofi Terramedic Incorporated
19.Nua
20.Cora

Frequently Asked Questions:

1] What is the growth rate of the Global Dysmenorrhea Treatment Market?
Ans. The Global Dysmenorrhea Treatment Market is growing at a significant rate of 8.4 % during the forecast period.

2] Which region is expected to dominate the Global Dysmenorrhea Treatment Market?
Ans. North America is expected to dominate the Dysmenorrhea Treatment Market during the forecast period.

3] What is the expected Global Dysmenorrhea Treatment Market size by 2029?
Ans. The Dysmenorrhea Treatment Market size is expected to reach USD 10457.37 Mn by 2029.

4] Which are the top players in the Global Dysmenorrhea Treatment Market?
Ans. The major top players in the Global Dysmenorrhea Treatment Market are Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC , Focus Consumer Healthcare and others.

5] What are the factors driving the Global Dysmenorrhea Treatment Market growth?
Ans. The increasing prevalence of Dysmenorrhea and growing research and development activities about Dysmenorrhea are expected to drive market growth during the forecast period.